On February 4, 2026, the Federal Trade Commission announced a settlement with Express Scripts, one of the largest pharmacy benefit managers, resolving the agency's lawsuit alleging that its conduct helped artificially inflate insulin prices. The settlement forces changes to how rebates are negotiated and passed through, and it lands on the same case that produced a similar agreement with another major middleman. For anyone filling a prescription, this is the part of the pricing system you never see — and it is now under a documented obligation to change.
What is a pharmacy benefit manager, and why does it set your price?
A pharmacy benefit manager sits between your insurer, the drugmaker and the pharmacy, deciding which drugs get preferred placement on formularies and negotiating rebates behind the sticker price. The FTC's core allegation was that rebate structures rewarded high list prices: the bigger the gap between list price and net price after rebates, the more the middleman could capture. You pay based on the list price and your plan's coverage rules, so inflated list prices inflate your copay even when someone in the chain is getting money back. The settlement targets exactly that structure for insulin, a category where list-versus-net gaps became notorious.
Related stories: FTC's Caremark settlement locks in up to $8.5 billion in savings · FTC is mailing $47.2 million in junk-fee refund checks.
What does the settlement actually change?
The agreement locks in changes to rebate and pricing practices rather than a simple cash payment, and it follows the FTC's earlier settlement with a different drug middleman in the same insulin case. The direction of the changes is consistent across both: reduce the incentive to favor high-rebate drugs, increase transparency about where rebate money flows, and pass more of the negotiated value to patients at the counter. Timelines for implementation roll out over months and years, not instantly — the settlement is a contract about future behavior, not a refund program you can claim this quarter.
Will your copay drop this year?
Treat that as an open question, not a promise. Insulin prices have already fallen for many patients through manufacturer list-price cuts and the $35 Medicare cap, so the settlement's incremental effect on any individual's copay depends on your plan's formulary design after the new rules settle in. What you can do now is practical rather than political: ask your pharmacist what the cash price is before insurance, because discount card cash prices on generic and older insulin sometimes beat the insured copay. Recheck your plan's formulary each open enrollment, because the drugs positioned at the lowest tier may shift as rebate rules change.
Why shoppers should watch this case at all
Prescriptions are one of the few purchases where you cannot comparison-shop your way out of a bad price, which is exactly why enforcement at the middleman layer matters. If the FTC's approach holds across the industry — two settlements so far, with the dominant firms covered — the structural incentive that kept list prices high weakens. That is the kind of price change that never gets a sale banner: no email, no clearance tag, just a copay that is lower at your next refill than it was at your last.
prices and policies change; check the retailer's current terms.